AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
ALISO VIEJO, Calif., Aug. 03, 2026 ( GLOBE NEWSWIRE ) -- AEON Biopharma, Inc. ( "AEON" or the "Company" ) ( NYSE American: AEON ) , a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® ( onabotulinumtoxinA ) for therapeutic use to achieve full-label U.S. market entry, today ...
Why it matters
Attributed market update with source link for portfolio context.